Anika Therapeutics Transforms to Hybrid Commercial Model

Anika Therapeutics reported 3Q19 orthopedic revenue of USD $26.8MM, +11.1% vs. 3Q18.

Anika provided updated 2019 full year revenue guidance in the range of $99.2MM to $100.2MM, representing growth of 6% to 7% over 2018
The company has embarked on a five-year strategic plan to achieve leadership in joint preservation and restoration,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us